Fulvestrant injection
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Royal Marsden NHS Foundation Trust, GOG Foundation, Institut Paoli-Calmettes, Kashiv BioSciences, LLC
Conditions
Advanced Breast CancerAdvanced MalignanciesAdvanced Solid TumorsAdvanced Unresectable or Metastatic Breast Cancer of AdultsBreast CancerCCCA Assessed by Ki67 Drop Below <2.7% From BaselineCervical CancerER+ Breast Cancer
Phase 1
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
NCT04355520
Start: 2020-07-31End: 2021-09-30Target: 42Updated: 2020-04-21
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers
Not yet recruitingNCT05986071
Start: 2024-05-01End: 2027-10-15Target: 57Updated: 2024-03-29
Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study
CompletedNCT06074757
Start: 2023-03-01End: 2023-10-01Updated: 2023-10-10
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
RecruitingNCT06202261
Start: 2023-04-13End: 2027-10-31Target: 154Updated: 2024-03-12
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
RecruitingNCT06208410
Start: 2024-01-11End: 2027-02-26Target: 306Updated: 2025-07-25
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
Not yet recruitingNCT06941142
Start: 2025-04-30End: 2028-06-30Target: 382Updated: 2025-04-23
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RecruitingNCT07109726
Start: 2025-09-23End: 2029-02-28Target: 205Updated: 2026-03-23
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
RecruitingNCT07389733
Start: 2026-03-27End: 2028-12-01Target: 180Updated: 2026-04-03
Phase 2
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
NCT04796623
Start: 2021-02-04End: 2023-01-31Target: 120Updated: 2021-03-15
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
RecruitingNCT04985266
Start: 2022-03-30End: 2030-09-01Target: 1100Updated: 2024-12-05
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Active, not recruitingNCT05154487
Start: 2024-09-11End: 2028-11-01Target: 51Updated: 2026-03-03
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
RecruitingNCT06607757
Start: 2024-12-04End: 2026-08-31Target: 120Updated: 2025-04-02
Phase 3
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Active, not recruitingNCT05365178
Start: 2022-07-01End: 2026-06-30Updated: 2026-01-07
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
RecruitingNCT06680921
Start: 2024-11-14End: 2028-08-31Target: 460Updated: 2025-09-22
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
Not yet recruitingNCT06929325
Start: 2025-04-30End: 2027-12-31Target: 312Updated: 2025-04-16
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
RecruitingNCT06998108
Start: 2022-06-09End: 2026-06-30Target: 330Updated: 2025-05-31
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
RecruitingNCT07024173
Start: 2025-07-23End: 2027-12-01Target: 240Updated: 2026-01-26